| INTRODUC TI ON
Respiratory syncytial virus (RSV) and influenza viruses cause substantial disease and economic burden. 1, 2 Surveillance systems in temperate countries demonstrate that RSV and influenza activity are seasonal and typically peak during colder months. [3] [4] [5] [6] In large countries like China and India, regional differences in respiratory virus activity can be substantial. 7, 8 These differences can be large enough that public health officials recommend administering different influenza vaccine formulations at different times of the year within the same country to mitigate seasonal activity. 9, 10 Regional differences in seasonal activity might also affect when persons at high risk of influenza-related complications are empirically treated with antivirals 11 and when RSV immunoprophylaxis is administered. 12 Optimizing the timing of these interventions may increase national coverage and cost-effectiveness. [6] [7] [8] 13, 14 It is therefore useful to establish the timing of RSV and influenza seasons to inform providers when they should anticipate administering virus-specific interventions.
Argentina's prevention and treatment guidelines for RSV and influenza are provided at the national level. Starting in 2015,
Argentina's Pediatric Society recommended the use of palivizumab, a monoclonal antibody, as a cost-effective method to prevent severe RSV illness among Argentinian children at high risk of hospitalizations due to RSV infection. 15 Specifically, the Society recommended that clinicians administer five doses of palivizumab (15 mg/kg) every 30 days during April-September for children aged ≤2 years with prematurity, congenital heart disease, or bronchopulmonary dysplasia. 16 Rodriguez et al 17 found that treating ~5
high-risk patients with palivizumab averted one RSV-associated hospitalization.
In addition, the 
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The deidentified data used in this study were collected via routine clinical and public health functions; their analysis was part of a program evaluation and not considered human subjects research. 29 690-71 041) for influenza. Of the 496 789 specimens tested for RSV, 24% (n = 118 329) were positive, and of the 520 116 specimens tested for influenza, 5% were positive (n = 24 700). Of the specimens tested for RSV, 64% were collected from the central region, 95% were collected at an inpatient setting, 49% were from children <1 year, and 24% were collected from children aged 1-5 years. Of the specimens tested for influenza, 65% were collected from the central region, 94% were collected at an inpatient setting, 47% were collected from children aged <1 year, and 23% were collected from children aged 1-5 years (Table 1 ).
| RE SULTS
In general, the median 10-year method resulted in a national RSV season that occurred during April-August (week 17-week 34), during which 21%-29% of respiratory specimens tested for RSV were positive ( (Table 2 ).
Among RSV-tested specimens, RSV positivity was highest among children aged <1 year (32%; n = 76 883) and aged 1-5 years (20%; n = 23 596) compared to any other age-group (P < 0.001) regardless of patient setting (Figure 1 ). Age data were missing for 68 627 (14%) specimens tested for RSV, of which 14 905 (22%) tested positive for the virus. In contrast, influenza positivity was highest among persons aged 15-64 years (P < 0.001; Figure 1 ). Age data were missing for 78 425 (15%) specimens tested for influenza, of which 3536 (5%) tested positive for the influenza virus.
According to the mean method, the national RSV activity peaked 
| D ISCUSS I ON
Our analysis of Argentinian surveillance data from 2007 to 2016
indicates that RSV and influenza cocirculated during the winter months, as has been observed in other temperate climates. Any policy change in influenza vaccine timing could be coupled with communication campaigns to improve influenza vaccine coverage.
29
In addition, region-specific knowledge of RSV activity is important to determine when to administer RSV-specific interventions such as palivizumab, as well as for any future vaccine and monoclonal antibody products in development. The cocirculation of RSV and influenza also has important implications for public health officials modeling the etiologic burden of disease in Argentina; because these viruses cocirculate, models must include robust age-specific virologic data to meaningfully attribute clinical syndromes like pneumonia to RSV and/or influenza infection. 32, 33 Certain limitations of these analyses should be considered. ). Given these limitations, expanding the geographic scope of influenza surveillance and increased respiratory testing among adults might be advantageous.
| CON CLUS IONS
Respiratory syncytial virus and influenza cocirculate during the winter months in Argentina and follow a seasonal pattern that starts as early as 
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